Agilent Technologies

Ottergemsesteenweg Zuid 808/bus 317
9000 Gent
BE
Agilent Technologies
Foundation date
01/01/1999
Sector
#Biotechnology / R&D ServicesSubsector
Therapeutic areas
- #Cardiovascular
- #Conditions originating in the perinatal period
- #Congenital malformations - deformations and chromosomal abnormalities
- #Digestive system
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the ear
- #Diseases of the eye
- #Diseases of the nervous system
- #Endocrine - nutritional and metabolic diseases
- #External causes of morbidity and mortality
- #Genitourinary system
- #Infectious and parasitic diseases
- #Injury - poisoning and certain other consequences of external causes
- #Mental and behavioural disorders
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Pregnancy - childbirth and the puerperium
- #Respiratory system
- #Skin and subcutaneous tissue
- #Symptoms - signs and abnormal clinical and laboratory findings - not elsewhere classified
Agilent inspires and supports discoveries that advance the quality of life. We provide life science, diagnostic, and applied market laboratories worldwide with instruments, services, consumables, applications, and expertise. Agilent enables customers to gain the answers and insights they seek ---- so they can do what they do best: improve the world around us.
The Agilent SLIMS platform provides technology that advances that goal, adding to Agilent’s substantial solutions. SLIMS traces its roots to 2002, where, in Ghent (Belgium), the startup company Genohm began as a small two-person bio-informatics shop. SLIMS today focuses on guaranteeing compliance, traceability and lab data management in highly complex and continuously evolving lab environments. Today, Agilent SLIMS is serviced by a global team of 60+ highly trained software and life sciences engineers. For more information on the SLIMS platform, visit: https://explore.agilent.com/Agilentslims.
The Alissa Clinical Informatics Platform delivers innovative NGS and CGH data analysis, variant interpretation and reporting modules designed to optimize workflows across technologies and applications. On the platform, integrate read alignment to reporting for greater efficiency. Interpret NGS and CGH data on a single sample to call CNVs via NGS data and run arrays as NGS tests for greater diagnostic yield. Shorten time to results by seamlessly flowing from raw data alignment, to annotations, to mutation categorisation. For more information on the Alissa Clinical Platform, visit: https://www.agilent.com/en/product/next-generation-sequencing/clinical-informatics-platform
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
18 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more